Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Sep;5(9):e607-e617.
doi: 10.1016/S2589-7500(23)00112-7. Epub 2023 Aug 3.

Integrating metabolic expenditure information from wearable fitness sensors into an AI-augmented automated insulin delivery system: a randomised clinical trial

Affiliations
Randomized Controlled Trial

Integrating metabolic expenditure information from wearable fitness sensors into an AI-augmented automated insulin delivery system: a randomised clinical trial

Peter G Jacobs et al. Lancet Digit Health. 2023 Sep.

Abstract

Background: Exercise can rapidly drop glucose in people with type 1 diabetes. Ubiquitous wearable fitness sensors are not integrated into automated insulin delivery (AID) systems. We hypothesised that an AID can automate insulin adjustments using real-time wearable fitness data to reduce hypoglycaemia during exercise and free-living conditions compared with an AID not automating use of fitness data.

Methods: Our study population comprised of individuals (aged 21-50 years) with type 1 diabetes from from the Harold Schnitzer Diabetes Health Center clinic at Oregon Health and Science University, OR, USA, who were enrolled into a 76 h single-centre, two-arm randomised (4-block randomisation), non-blinded crossover study to use (1) an AID that detects exercise, prompts the user, and shuts off insulin during exercise using an exercise-aware adaptive proportional derivative (exAPD) algorithm or (2) an AID that automates insulin adjustments using fitness data in real-time through an exercise-aware model predictive control (exMPC) algorithm. Both algorithms ran on iPancreas comprising commercial glucose sensors, insulin pumps, and smartwatches. Participants executed 1 week run-in on usual therapy followed by exAPD or exMPC for one 12 h primary in-clinic session involving meals, exercise, and activities of daily living, and 2 free-living out-patient days. Primary outcome was time below range (<3·9 mmol/L) during the primary in-clinic session. Secondary outcome measures included mean glucose and time in range (3·9-10 mmol/L). This trial is registered with ClinicalTrials.gov, NCT04771403.

Findings: Between April 13, 2021, and Oct 3, 2022, 27 participants (18 females) were enrolled into the study. There was no significant difference between exMPC (n=24) versus exAPD (n=22) in time below range (mean [SD] 1·3% [2·9] vs 2·5% [7·0]) or time in range (63·2% [23·9] vs 59·4% [23·1]) during the primary in-clinic session. In the 2 h period after start of in-clinic exercise, exMPC had significantly lower mean glucose (7·3 [1·6] vs 8·0 [1·7] mmol/L, p=0·023) and comparable time below range (1·4% [4·2] vs 4·9% [14·4]). Across the 76 h study, both algorithms achieved clinical time in range targets (71·2% [16] and 75·5% [11]) and time below range (1·0% [1·2] and 1·3% [2·2]), significantly lower than run-in period (2·4% [2·4], p=0·0004 vs exMPC; p=0·012 vs exAPD). No adverse events occurred.

Interpretation: AIDs can integrate exercise data from smartwatches to inform insulin dosing and limit hypoglycaemia while improving glucose outcomes. Future AID systems that integrate exercise metrics from wearable fitness sensors may help people living with type 1 diabetes exercise safely by limiting hypoglycaemia.

Funding: JDRF Foundation and the Leona M and Harry B Helmsley Charitable Trust, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests PGJ and JRC have a financial interest in Pacific Diabetes Technologies, a company that might have a commercial interest in the results of this research and technology. JRC also reports advisory board participation for Zealand Pharma, Novo Nordisk, Insulet, and AstraZeneca. PGJ reports advisory board participation for Eli Lilly. PGJ and JRC have received research funding at their institution from Dexcom. All other authors declare no competing interests.

Figures

Figure 1:
Figure 1:. iPancreas system
The system comprises a Dexcom G6 CGM, an Insulet Omnipod along with a relay PDM, a Polar M-600 smartwatch with heart rate and accelerometer sensors, and a Samsung smartphone running the exAPD or exMPC control algorithms. AWS=Amazon Web Services. exAPD=exercise-aware adaptive proportional derivative. exMPC=exercise-aware model predictive control. PDM=personal diabetes manager.
Figure 2:
Figure 2:. Trial profile
exAPD=exercise-aware adaptive proportional derivative. exMPC=exercise-aware model predictive control.
Figure 3:
Figure 3:. CGM data, insulin, and METs during the primary in-clinic session (0700–1900 h)
Middle plots show how the exMPC tended to reduce insulin earlier in the day when activities of daily living were taking place, whereas, the exAPD only shut off insulin when the structured exercise took place later in the day. CGM=continuous glucose monitor. exAPD=exercise-aware adaptive proportional derivative. exMPC=exercise-aware model predictive control. MET=metabolic equivalent to task.
Figure 4:
Figure 4:. CGM data, insulin, and METs during the 2 h after the start of the primary in-clinic session structured exercise
The exercise-aware model predictive control (exMPC) algorithm data are shown on the right panel and the exercise-aware adaptive proportional derivative (exAPD) algorithm data are shown on the left panel. Notice that the exAPD shuts off insulin completely once structured exercise is detected while the exMPC will only shut off insulin completely if necessary. CGM=continuous glucose monitor. MET=metabolic equivalent to task.

Comment in

Similar articles

Cited by

References

    1. Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 2016; 316: 1407–08. - PubMed
    1. Brown SA, Forlenza GP, Bode BW, et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care 2021; 44: 1630–40. - PMC - PubMed
    1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019; 381: 1707–17. - PMC - PubMed
    1. Ware J, Boughton CK, Allen JM, et al. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. Lancet Digit Health 2022; 4: e245–55. - PubMed
    1. Tsoukas MA, Majdpour D, Yale J-F, et al. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial. Lancet Digit Health 2021; 3: e723–32. - PubMed

Publication types

Associated data